Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Studie: AIO KRK 0207; Indikation: Kolorektalkarzinom; Jahr: 2015; Veranstaltung: -; Journal: The Lancet